A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Completed · Phase 3 · NCT03069352
Conditions: Acute Myeloid Leukemia (AML)
At a glance
- Research payments reported, 2025
- $11,008
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 211
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo (drug), Venetoclax (drug), Cytarabine (drug)
- Dates
- Started 2017-05-29; completion 2025-08-21
- Results posted
- Yes
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).
From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $11,008 in research payments for this study in 2025 (7 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Norton Healthcare Inc $11,008
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.